Forte Biosciences, Inc. — Director's Dealing 2017

Apr 21, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Tocagen Inc (TOCA)
CIK: 0001419041
Period of Report: 2017-04-19

Reporting Person: BERGER FRANKLIN M (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-04-19	Common Stock	J	25335	$10.00	Acquired	25335	Direct

Footnotes

F1: Represents the conversion of an outstanding convertible promissory note in the principal amount of $250,000, plus $3,356.16 accrued interest, into shares of the Issuer's common stock upon closing of the Issuer's initial public offering at a conversion price of $10.00 per share.